All In MedTech

FDA Clearance Tracker · P100020-S055

cobas HPV Test

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: May 14, 2024 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

May 14, 2024

Approved

Time to decision

372 days

Received May 8, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P100020-S055
Device name
cobas HPV Test
Applicant location
Pleasanton, CA
Received
May 8, 2023
Decided
May 14, 2024
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P100020

Device type

Device class
Class III

Every decision under product code MAQ

FDA's approval statement

As written in FDA's record.

Approval for using self-collected vaginal specimens, obtained in a healthcare setting, which can be tested as an alternative specimen type when cervical sampling is either contraindicated or cervical samples otherwise cannot be obtained.

Source documents

Other decisions for Roche Molecular Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.